PRX-112

Protalix Drug in Phase IIa Study for Gaucher Disease
Yahoo/Zacks.com
Fri, 06/20/14 - 11:02 am
Protalix BioTherapeutics
Gaucher disease
PRX-112
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Yahoo/Globe Newswire
Wed, 06/18/14 - 09:45 am
PRX-112
Protalix BioTherapeutics
Gaucher disease